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introduction: Upregulating endogenous apolipoprotein A-I (apoA-I) is considered an attractive means of targeting HDL function. The effect of this 
strategy in patients stratified to baseline degrees of systemic inflammation has not been investigated.
methods: 323 patients with coronary disease and low HDL-C levels were randomized to treatment with the apoA-I inducer, RVX-208 100 mg twice 
daily or placebo for 26 weeks. Serial coronary intravascular ultrasound was performed to evaluate the impact on atheroma progression. The effects 
on disease progression and major adverse cardiovascular events (MACE: death, myocardial infarction, stroke, coronary revascularization, hospitalization 
for unstable angina or heart failure) were evaluated in patients with baseline C-reactive protein (CRP) levels < than vs. ≥ than 2 mg/L.
results: Increases in apoA-I by 12.8% (P<0.001) and HDL-C by 11.1% (P<0.001) compared with baseline were observed in the RVX-208 group. 
RVX-208 was associated with a reduction in percent atheroma volume (PAV) and total atheroma volume (TAV) in patients with CRP ≥ 2mg/dL. 
Such benefits were not observed with RVX-208 in patients with CRP <2mg/dL. A lower MACE rate was observed in RVX-208-treated patients (6.9 vs. 
18.9%, P=0.02) in patients with CRP ≥2mg/dL (Table).
conclusion: Potentially more favorable effects of the apoA-I inducer, RVX-208, on coronary disease progression and MACE were observed in 
patients with higher levels of systemic inflammation.
Parameter CRP <2 mg/L CRP >2 mg/L
Placebo
(n=27)
RVX-208 (n=111) P Value
Placebo
(n=53)
RVX-208 (n=130) P Value
PAV (%)
Median (IQR)
0.6 (-1.5, 1.4) 0 (-1.6, 1.4) 0.72 -0.5 (-2.0, 0.8) -0.7 (-2.0, 1.2) 0.98
P=0.81* P=0.78* P=0.08* P=0.04*
TAV (mm3)
Median (IQR)
-3.8 (-9.8, 5.3) 0.8 (-11.9, 7.1) 0.71 -3.1 (-12.4, 2.8) -5.7 (-18.1, 4.4) 0.45
P=0.30* P=0.39* P=0.02* P<0.001*
MACE (%) 3.7 8.1 18.9 6.9 0.02
*denotes within-grp P-value
